Computational modelling and inhibitor risk: Predicting the future?

Haemophilia

Volumn 20, Issue 2, 2014, Pages 155-157

  Hart, D P ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FACTOR VIII; HEMOPHILIA A; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; ISOANTIBODIES; MUTATION, MISSENSE; PEPTIDE FRAGMENTS;

EID: 84894263022     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12332     Document Type: Editorial

References (19)

1. Hay CR, Ollier W, Pepper L et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 234-7.
2. Oldenburg J, Picard JK, Scwaab R et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-42.
3. 593 to Cys mutation. Haemophilia 2004; 10: 509-14.
4. Pashov AD, Calvez T, Gilardin L et al. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia 2013. (in press).
5. Eckhardt CL, van Velzen AS, Peters M et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere haemophilia A. Blood 2013; 122: 1954-62.
6. Jacquemin M, Vantomme V, Buhot C et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003; 101: 1351-8.
7. James EA, vanHaren SD, Ettinger RA, et al. T-cell responses in two unrelated haemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site. J Thromb Haemost 2011; 9: 689-99.
8. Intergovernmental panel on climate change: climate change 2013, The Physical Science Basis - Fifth assessment report (AR5) 2013.
9. Lundegaard C, Hoof I, Lund O et al. State of the art and challenges in sequence based T-cell epitope prediction. Immunome Res 2010; 6(Suppl. 2): S3.
10. Bjorkman PJ, Saper MA, Samraoul B et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329: 506-12.
11. Lin HH, Ray S, Tongchusak S et al. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol 2008; 9: 8.
12. Patronov A, Doytchinova I. T-cell epitope vaccine design by immunoinformatics. Open Biol 2013; 3: 120139.
13. MacNamara A, Kadolsky U, Bangham CR et al. T-cell epitope prediction: rescaling can mask biological variation between MHC molecules. PLoS Comput Biol 2009; 5: e1000327.
14. Brown JH, Jardetzky TS, Gorga JC et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364: 33-9.
15. Stern LJ, Brown JH, Jardetzky TS et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368: 215-21.
16. Nielsen M, Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009; 10: 296.
17. Pandey GS, Yanover C, Howard TE et al. Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia A: a computational assessment. PLoS Comput Biol 2013; 9: e1003066.
18. Sauna ZE, Ameri A, Kim B et al. Observations regarding the immunogenicity of BDD-rFVIII derived from a mechanistic personalized medicine perspective. J Thromb Haemost 2012; 10: 1961-5.
19. van Haren SD, Herczenik E, ten Brinke A et al. HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII. Mol Cell Proteomics 2011; 10: M110.